Redwood Grove Capital LLC Takes $18.07 Million Position in IQVIA Holdings Inc. $IQV

Redwood Grove Capital LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 93,500 shares of the medical research company’s stock, valued at approximately $18,066,000. IQVIA accounts for 4.6% of Redwood Grove Capital LLC’s holdings, making the stock its 10th biggest holding.

Several other hedge funds have also recently bought and sold shares of the stock. International Assets Investment Management LLC acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. Compass Financial Management LLC acquired a new stake in shares of IQVIA during the second quarter worth $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA in the 4th quarter valued at $27,000. CrossGen Wealth LLC acquired a new position in IQVIA in the 4th quarter worth $28,000. Finally, Activest Wealth Management increased its holdings in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.1%

Shares of IQV stock opened at $259.97 on Wednesday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $261.88. The stock has a market cap of $42.79 billion, a price-to-earnings ratio of 32.25, a PEG ratio of 2.21 and a beta of 1.18. The firm’s 50-day moving average is $216.59 and its 200-day moving average is $188.02. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the business earned $2.81 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have recently weighed in on IQV shares. BMO Capital Markets upped their price objective on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Stifel Nicolaus upped their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Mizuho raised their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 over the last 90 days. 1.70% of the stock is owned by insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.